CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (34,242)	$ (62,328)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	19,069	15,684
Non-cash operating lease costs	10,113	0
Stock-based compensation	23,866	59,855
Amortization of discount and debt issue costs	549	295
(Gain) loss on remeasurement of contingent consideration	(1,037)	434
Loss on disposal of assets	45	0
Change in operating assets and liabilities, net of businesses acquired:
Patient accounts receivable, net	(17,138)	(18,121)
Prepaid expenses and other current assets	(4,543)	(12,065)
Accounts payable	(5,466)	1,852
Accrued payroll expenses	7,663	12,759
Operating lease liabilities	(8,736)	0
Other accrued expenses	1,967	4,943
Net cash (used in) provided by operating activities	(7,890)	3,308
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(7,729)	(27,910)
Acquisitions of businesses, net of cash acquired	(19,820)	(22,945)
Net cash used in investing activities	(27,549)	(50,855)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from long-term debt	0	20,000
Payments of long-term debt	(586)	(331)
Payments of contingent consideration	(4,302)	(5,720)
Taxes related to net share settlement of equity awards	0	(441)
Net cash (used in) provided by financing activities	(4,888)	13,508
NET DECREASE IN CASH AND CASH EQUIVALENTS	(40,327)	(34,039)
Cash and Cash Equivalents - Beginning of period	108,621	148,029
CASH AND CASH EQUIVALENTS – END OF PERIOD	68,294	113,990
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest	5,059	3,091
Cash paid for taxes, net of refunds	(13)	(60)
SUPPLEMENTAL DISCLOSURES OF NON CASH INVESTING AND FINANCING ACTIVITIES
Equipment financed through finance leases	0	57
Contingent consideration incurred in acquisitions of businesses	1,985	2,470
Acquisition of property and equipment included in liabilities	$ 8,297	$ 12,320